Stat’s Andrew Joseph and Helen Branswell on the short-term, middle-term, and long-term future of the coronavirus in the US. The short-term outlook is dominated by vaccination & variants; some parts of the country will continue to be affected by outbreaks:
Conditions may be ripe for a better summer, however. Vaccine supplies should be flowing more freely, at least in the U.S.; the Biden administration now expects enough vaccine doses in hand for all adults by the end of May. With most vulnerable populations protected, there should be fewer hospitalizations and deaths. And with warmer weather, people can return to outdoor life.
Widespread transmission of the virus could be replaced by more sporadic and localized outbreaks. There’s also growing evidence that vaccines don’t just protect people from getting symptomatic Covid-19, but can reduce transmission.
And in the long-term, well, SARS-CoV-2 will be around for years and even decades to come:
Years from now, SARS-CoV-2 could join the ranks of OC43, 229E, NL63, and HKU1 — the four endemic, seasonal coronaviruses that cause a chunk of common colds every year. Essentially, our immune systems — primed by vaccines, boosters, and previous encounters with the coronavirus — will be ready to knock back SARS-2 when we see it again, potentially blocking an infection or leading to one that causes no symptoms or maybe just the sniffles.
It’s good to read stuff like this — it provides a basis to use when calibrating your optimism or pessimism for future activities and desires.
Tags: Andrew Joseph COVID-19 Helen Branswell medicine science USA vaccinesfrom kottke.org https://ift.tt/3chONpT
via IFTTT
EmoticonEmoticon